SCHEMBL5510141

SCHEMBL5510141

O=C(CS(=O)(=O)N1CCC1)c1ccccc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 3/20 0.49
TSHR P16473 2/20 0.49
L3MBTL1 Q9Y468 1/20 0.46
KMT2A Q03164 5/20 0.46
ALDH1A1 P00352 5/20 0.46
RECQL P46063 1/20 0.45
GFER P55789 1/20 0.45
MAPT P10636 2/20 0.44
MAPK1 P28482 2/20 0.44
KDM4E B2RXH2 1/20 0.44
MEN1 O00255 1/20 0.44
CYP3A4 P08684 1/20 0.44
ALOX15 P16050 1/20 0.44
CES1 P23141 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
POLB P06746 1/20 0.43
LMNA P02545 1/20 0.43
IL1RN P18510 1/20 0.43
CYP1A2 P05177 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25490049 0.95 HPGD (0.56) HPGDTSHRL3MBTL1KMT2AALDH1A1
SCHEMBL12576431 0.80 POLB (0.50) HPGDTSHRKMT2AALDH1A1MAPT
SCHEMBL14452167 0.79 MEN1 (0.61) L3MBTL1KMT2AALDH1A1MEN1SMN1; SMN2
SCHEMBL1266470 0.79 AKR1C3 (0.56) L3MBTL1KMT2AALDH1A1MAPTKDM4E
SCHEMBL10898262 0.75 KMT2A (0.50) KMT2AMEN1
SCHEMBL1516246 0.73 MAPK1 (0.58) HPGDTSHRL3MBTL1KMT2AALDH1A1
SCHEMBL137832 0.71 MAPK1 (0.56) HPGDTSHRL3MBTL1KMT2AALDH1A1
SCHEMBL6203436 0.71 ATM (0.46) L3MBTL1KMT2AALDH1A1MAPTMAPK1
SCHEMBL1266219 0.70 HSD11B1 (0.54) HPGDTSHRKMT2AALDH1A1MAPT
SCHEMBL6202187 0.70 MAPT (0.53) L3MBTL1KMT2AALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7250444-B2 Pyrrole-based HMG-CoA reductase inhibitors PFIZER INC. (US) 2007-07-31 US disclosed
US-7250444-B2 Pyrrole-based HMG-CoA reductase inhibitors PFIZER INC. (US) 2007-07-31 US disclosed
US-7250444-B2 Pyrrole-based HMG-CoA reductase inhibitors PFIZER INC. (US) 2007-07-31 US disclosed
US-20060287378-A1 Novel pyrroles and imidazoles WARNER-LAMBERT COMPANY LLC 2006-12-21 US disclosed
US-20050043364-A1 Novel pyrrole-based HMG-CoA reductase inhibitors KENNEDY ROBERT MICHAEL (US) 2005-02-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050043364-A1 Novel pyrrole-based HMG-CoA reductase inhibitors HMGCR, DHCR7, HSD17B12 HPGD 69/4885TSHR 4025/4885L3MBTL1 4129/4885
US-20060287378-A1 Novel pyrroles and imidazoles PPIP5K2, PPIE, PPOX HPGD 150/4885TSHR 2795/4885L3MBTL1 4821/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.